Background: In people with Rheumatoid arthritis (RA) impaired physical functioning is an acute as well as long term effect of the disease. Observational performance tests reflecting range of motion in upper as well as in lower extremities should be easy to perform in the clinic as well as in research as a complement to self-reported measures of physical functioning. The Signal Of Functional Impairment (SOFI) 1 is a performance test which so far has been applied only in Sweden but commonly used in the clinic and in long term follow-up clinical studies. Objectives: The aim was to study performance-based function assessed with SOFI over 8 years and, secondly, to study which items included in SOFI that were associated with change in functioning over time. Methods: An inception cohort of 1 052 patients with early RA, from the BARFOTstudy, recruited 1992-2006 was investigated, mean (SD) age was 54 years (14), 70% were women. The patients were followed by a structured protocol at baseline, 3 and 6 months and at 1, 2, 5, and 8 years. SOFI consists of 3 parts measuring hand, arm (upper), and leg (lower) function (1). Hand function is tested by 4 movements; cylinder grip (H1), pen grip (H2), pincer grip (H3) and opposition of the thumb (H4). Arm function is assessed by 3 movements; hand behind the head and the ability to touch the cervical spine processes with fingers (A1), elbow supination (A2) and elbow extension (A3). Leg function is tested by 4 movements; the ability to touch the opposite knee with the heel while sitting (L1), knee extension in supine position (L2), dorsiflexion of the foot standing on a balance board (L3), and the ability to stand on tip toes without shoes (L4). An assessor scores the patient's ability to perform the different tests on an ordinal scale (0=normal, 1= partly impaired and 2= unable to perform). The range of SOFI scores is 0-44 (best to worst). Results: At baseline the mean (SD) SOFI was 7.2 (5.8), and at 1 year follow-up the improvement was 2.75 (5.65), p<0.001. From 1 year to 8 year follow-up the deterioration was 1.5 (4.6), p<0.001. When studying hand, upper and lower function separately, the pen grip and the ability to stand on tip toes improves most during the first year. From 1 to 8 year the pincer grip and the ability to stand on tip toes are the items that deteriorate most (Figure) . Assessment of the pen grip, the pincer grip and the ability to stand on tip toes explain 58% to 70% of the SOFI score over time, with the highest rate at 5 (65%) and 8 years follow-up (70%).
Conclusions:
Functioning as assessed by SOFI improved during the first year in patients with early RA and then deteriorated slowly. Over a longer period, pincer grip and the ability to stand on tip toes seemed to be the two most important items to measure when assessing functional impairment over time. Background: Evidence shows that remission can be maintained in selected patients whose biologic medication is dose tapered 1 . In June 2015 we began tapering the doses of selected rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis patients in disease remission. The process was agreed with the local commissioners and a protocol 2 was devised to guide safe and evidence based biologic dose tapering. Benefits include reduced medication burden for patients, fewer day-case infusions and financial savings. However, there is a lack of knowledge of patients' perceptions of the process. Objectives: Our department proposed to investigate patients' perceptions of their experience of dose tapering. We wanted to assess patients' understanding and acceptance of the process and ensure they felt included in decision making. Patient feedback enables reflection and improved practice. Methods: An anonymous, tick-box, patient satisfaction survey was devised. It requested that patients stated the extent to which they agreed with a statement, also allowing free-text comments. The survey was posted to relevant patients after their identification from our biologics database. A stamped addressed envelope was provided for return of the completed survey.
Results: 56 surveys were posted, 46 (82%) were returned. 31 (67%) of patients were pleased to taper their medication, 35 (76%) felt fully included in decision making and 36 (78%) agreed that they had the opportunity to ask questions. Of the 13 patients whose disease flared post-taper, 8 (62%) agreed that they were promptly reviewed in clinic, 1 patient (8%) disagreed. Some admitted to anxiety prior to dose tapering, however once established on their new dose, continuing disease remission was reassuring. Patients felt that they could contact the rheumatology helpline if required. Some also expressed that their quality of life had improved due to the decreased medication burden. 6 (37.5%) of the 16 rituximab patients who replied, disagreed that they were included in the decision to dose taper. Therefore, clinicians must ensure information provided is clear, that a full discussion occurs and the patient has an opportunity to ask questions. On review, it was evident that the wording of the survey may have caused confusion for rituximab patients. The term "dose reduction" may have suggested that the dose of medication in their infusion was reduced. In practice, the patient decreased from two infusions to one. Conclusions: The majority of patients expressed that they were content with the biologic dose tapering process and felt sufficiently included in decision making. Importantly, a large proportion of patients were of the opinion that they were reviewed quickly when their disease flared. Practice can be improved from the knowledge that some patients would appreciate more communication regarding the decision to dose taper. Also, when undertaking further patient surveys, questions must be clear and unambiguous. Background: Fibromyalgia (FM) is a chronic non inflammatory condition characterized by pain and fatigue as well as physical and psychological symptoms. Management can be particularly challenging and a combination of pharmacological and non pharmacological treatments are recommended. Objectives: The aim was to study the level of anxiety and depression in fibromyalgia patients and whether these were associated with symptom severity, functional status, social or demographic factors. Methods: A cross sectional survey of 155 consecutive patients attending the nurse-led fibromyalgia clinic was carried out. Patients were diagnosed using the 2010 ACR diagnostic criteria. Demographic data, Widespread Pain Index (WPI), Symptom Severity Score (SSS), VAS pain and VAS fatigue were recorded. Patients filled in the self-administered questionnaires including the Revised fibromyalgia impact questionnaire (FIQR), Hospital Anxiety and Depression Scale (HADS). Patients were classified as suffering from high anxiety or depression if HADS was ≥11, moderate if 8-10 and low ≤7 for each scale respectively. Cross tabs and chi squared were used to study associations between anxiety and depression and social and demographic factors. Logistic regression analysis was performed to identify whether WPI, SSS, FIQR, VAS pain and VAS fatigue were predictors of severe anxiety and depression. Results: One hundred fifty five patients (92% female) participated in the survey. The average age was 50.3 years (SD 11.5) and mean duration of symptoms 13.4 years (SD 11.3). The mean HADS-A (anxiety) was 11.8 (SD 4.13), HADS-D (depression) 9.1 (SD 3.8) and FIQR 60.3 (SD 17.6). High levels of depression were reported by 31.5%, moderate 32.1% and low 30.3%. High levels of anxiety were reported by 60%, moderate 21.2% and low 13.3%. Both high levels of anxiety and depression were found in 25.2% of patients. SSS was the single best predictor for anxiety (p=0.001) while disease duration (p=0.01), SSS (p=0.02) and FIQR (0.04) predicted depression. VAS pain and VAS fatigue were not good predictors of severe anxiety and depression. When patients with high levels of anxiety and depression were compared with those with moderate and lower levels no association was found with age or social factors including occupation, marital status, level of education and family support. Conclusions: Both severe anxiety and depression were highly prevalent in our FM cohort, particularly anxiety. All FM patients need to be screened for anxiety and depression particularly those with high SSS and FIQR scores and longer disease duration. A psychiatrist and psychotherapist with a special interest in FM are essential members of the multidisciplinary team to ensure that anxiety and depression are addressed early prior to starting further interventions for FM.
References:
[1] Jensen KB, Fransson P, Marcus HM, Williams SCR, Choy E, Mainguy Y, Gracely R, Ingvar M, Kosek E (2010) anxiety and depression in fibromyalgia
